［1］DURER C,DURER S,LEE S,et al.Treatment of relapsed multiple myeloma:Evidence-based recommendations［J］.Blood Reviews,2019,39:100616.
［2］PALLADINI G,MILANI P,MALAVASI F,et al.Daratumumab in the treatment of light-chain(AL) amyloidosis［J］.Cells,2021,10(3):505.
［3］SALTARELLA I,DESANTIS V,MELACCIO A,et al.Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma［J］.Cells,2020,9(1):167.
［4］FRANSSEN LE,STEGE C,ZWEEGMAN S,et al.Resistance mechanisms towards CD38 directed antibody therapy in multiple myeloma［J］.Journal of Clinical Medicine,2020,9(4):1195.
［5］WUDHIKARN K,WILLS B,LESOKHIN AM.Monoclonal antibodies in multiple myeloma:Current and emerging targets and mechanisms of action［J］.Best Practice and Research in Clinical Haematology,2020,33(1):101143.
［6］DIMA D,DOWER J,COMENZO RL,et al.Evaluating daratumumab in the treatment of multiple myeloma:Safety,efficacy and place in therapy［J］.Cancer Management and Research,2020,12:7891-7903.
［7］MARKOVIC U,ROMANO A,FABRO VD,et al.Daratumumab as single agent in relapsed/refractory myeloma patients:A retrospective real-life survey［J］.Frontiers in Oncol,2021,11:624405.
［8］GARCIA-GUERRERO E,GOTZ R,DOOSE S,et al.Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab［J］.Leukemia,2020,35(1):1-14.
［9］SPENCER A,LENTZSCH S,WEISEL K,et al.Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma:updated analysis of CASTOR［J］.Haematologica,2018,103(12):2079-2087.
［10］DIMOPOULOS MA,ORIOL A,NAHI H,et al.Daratumumab,lenalidomide,and dexamethasone for multiple myeloma［J］.N Engl J Med,2016,375(14):1319-1331.
［11］SANCHEZ L,RICHTER J,CHO HJ,et al.Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma［J/OL］.Therapeutic Advances in Hematology.(2021-12-01).https://doi.org/10.1177/2040620720987075.
［12］MOREAU P,ATTAL M,HULIN C,et al.Bortezomib,thalidomide,and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA):a randomised,open-label,phase 3 study［J］.Lancet,2019,394(10192):29-38.
［13］MATEOS MV,DIMOPOULOS MA,CAVO M,et al.Daratumumab plus bortezomib,melphalan,and prednisone for untreated myeloma［J］.N Engl J Med,2018,378(6):518-528.
［14］SYED YY.Daratumumab:A review in combination therapy for transplant-ineligible newly diagnosed multiple myeloma［J］.Drugs,2019,79(4):447-454.
［15］RAJKUMAR SV.Multiple myeloma:2020 update on diagnosis,risk-stratification and management［J］.American Journal of Hematology,2020,95(5):548-567.
［16］LANDGREN CO,CHARI A,COHEN YC,et al.Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma:a randomized,open-label,multicenter,phase 2 study(CENTAURUS)［J］.NPG Open Access,2020,34(7):1840-1852.
［17］OFFIDANI M,CORVATTA L,MORE S,et al.Daratumumab for the management of newly diagnosed and relapsed/refractory multiple myeloma:Current and emerging treatments［J］.Frontiers in Oncol,2021,10:624661.
［18］ROCCATELLO D,FENOGLIO R,SCIASCIA S,et al.CD38 and anti-CD38 monoclonal antibodies in AL amyloidosis:Targeting plasma cells and beyond［J］.International Journal of Molecular Sciences,2020,21(11):4129.
［19］SANCHORAWALA V,SAROSIEK S,SCHULMAN A,et al.Safety,tolerability,and response rates of daratumumab in relapsed AL amyloidosis:Results of a phase Ⅱ study［J］.Blood,2020,135(18):1541-1547.
［20］PALLADINI G,KASTRITIS E,MAURER MS,et al.Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis:safety run-in results of ANDROMEDA［J］.Blood,2020,136(1):71-80.
［21］SHRAGAI T,GATT M,LAVIE N,et al.Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials:A multisite study and systematic literature review［J］.European Journal of Haematology,2021,106(2):184-195.
［22］KAUFMAN GP,CERCHIONE C.Beyond andromeda:Improving therapy for light chain amyloidosis［J］.Frontiers in Oncol,2021,10:624573.
［23］JERYCZYNSKI G,ANTLANGER M,DUCA F,et al.First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis:the real-world experience［J］.ESMO Open,2021,6(2):100065.
［24］KIMMICH CR,TE RZER T,BENNER A,et al.Daratumumab for systemic AL amyloidosis:prognostic factors and adverse outcome with nephrotic-range albuminuria［J］.Blood,2020,135(18):1517-1530.
［25］MILANI P,FAZIO F,BASSET M,et al.High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain(AL) amyloidosis and high bone marrow plasma cell infiltrate［J］.American Journal of Hematology,2020,95(8):900-905.
［26］ROUSSEL M,MERLINI G,CHEVRET S,et al.A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis［J］.Blood,2020,135(18):1531-1540.
［27］KASTRITIS E,THEODORAKAKOU F,ROUSSOU M,et al.Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance［J］.Br J Haematol,2021,193(1):113-118.
［28］DAMLE RN,WASIL T,FAIS F,et al.IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia［J］.Blood,1999,94(6):1840-1847.
［29］MANNA A,AULAKH S,JANI P,et al.Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia(CLL)［J］.Clin Cancer Res,2019,25(13):3974-3985.
［30］SALLES G,GOPAL AK,MINNEMA MC,et al.Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma,diffuse large B-cell lymphoma,and follicular lymphoma［J］.Clin Lymphoma,Myeloma Leuk,2019,19(5):275-284.
［31］VIDAL-CRESPO A,MATAS-CESPEDES A,RODRIGUEZ V,et al.Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens［J］.Haematologica,2019,105(4):1032-1041.
［32］HUANG H,ZHU J,YAO M,et al.Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma,nasal type:an open-label,single-arm,multicenter,phase 2 study［J］.J Hematol Oncol,2021,14(1):25.
［33］XUE W,ZHANG M.Updating targets for natural killer/T-cell lymphoma immunotherapy［J］.Cancer Bio Medicine,2021,18(1):52-62.
［34］KREJCIK J,FRERICHS KA,NIJHOF IS,et al.Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab［J］.Clin Cancer Res,2017,23(24):7498-7511.
［35］TAYLOR RP,LINDORFER MA.Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms:Rational design of dosing strategies［J］.Molecular Pharmacology,2014,86(5):485-491.
［36］LOKHORST HM,PLESNER T,LAUBACH JP,et al.Targeting CD38 with daratumumab monotherapy in multiple myeloma［J］.N Engl J Med,2015,373(13):1207-1219.
［37］NIJHOF I,CASNEUF T,VAN VELZEN J,et al.CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma［J］.Blood,2016,128(7):959-970.
［38］NOOKA A,KAUFMAN J,HOFMEISTER C,et al.Daratumumab in multiple myeloma［J］.Cancer,2019,125(14):2364-2382.
［39］DECKERT J,WETZEL MC,BARTLE LM,et al.SAR650984,a novel humanized CD38-targeting antibody,demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies［J］.Clin Cancer Res,2014,20(17):4574-4583.
［40］PAWEL R,IZABELA D,JANUSZ S,et al.Drug resistance in multiple myeloma［J］.Cancer Treatment Reviews,2018,70:199-208.